Evidence map›Paper›PMID 31919745›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2020

Construction of

Xiaoyi Guo, Nina Zhou, Zuhua Chen, Teli Liu, Xiaoxia Xu, Xia Lei, Lin Shen, Jing Gao, Zhi Yang, Hua Zhu

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Evaluation ofACS omega · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. Development and clinical evaluation of [European journal of nuclear medicine and molecular imaging · 2025
    Article
  8. Advances and challenges in immunoPET methodology.Frontiers in nuclear medicine · 2024
    Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. [Molecules (Basel, Switzerland) · 2022
    Article
  14. Pre-Clinical Study of the [Frontiers in medicine · 2022
    Article
  15. Review
  16. Review
  17. Theranostic Advances in Breast Cancer in Nuclear Medicine.International journal of molecular sciences · 2021
    Review
  18. PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology.International journal of molecular sciences · 2021
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 2 countries.

Xiaoyi GuoKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, No. 52 Fucheng Rd., Beijing, 100142, China.
Nina ZhouKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, No. 52 Fucheng Rd., Beijing, 100142, China.
Zuhua ChenDepartment of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Teli LiuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, No. 52 Fucheng Rd., Beijing, 100142, China.
Xiaoxia XuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, No. 52 Fucheng Rd., Beijing, 100142, China.
Xia LeiKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, No. 52 Fucheng Rd., Beijing, 100142, China.
Lin ShenDepartment of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Jing GaoDepartment of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Zhi YangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, No. 52 Fucheng Rd., Beijing, 100142, China. pekyz@163.com.ORCID 0000-0003-2084-5193
Hua ZhuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, No. 52 Fucheng Rd., Beijing, 100142, China. zhuhuananjing@163.com.
Peking University · CN

Funding

Beijing Excellent Talents Funding 2017000021223ZK33Beijing Municipal Administration of Hospitals-Yangfan Project ZYLX201816Beijing Natural Science Foundation, JingJin-Ji special projects for basic research cooperation H2018206600Beijing Nova Program Z171100001117020National Key Research and Development Program of China 2017YFC1308900National Natural Science Foundation of China 81571705NationalNatural Science Foundation of China 81671733NationaNatural Science Foundation of China 81871386
6 · The paper itself

Abstract

purposeHere, we sought to develop a PET radioligand based on trastuzumab labeled with

methodsIn animal studies, micro-PET imaging and bio-distribution were performed to examine the specificity of

resultsIn animal studies, PET imaging of

conclusionThe findings described here demonstrated that

Indexed as

AdultAgedAnimalsAntineoplastic Agents, ImmunologicalApoptosisCell ProliferationErb-b2 Receptor Tyrosine KinasesFemaleFluorodeoxyglucose F18HumansIodine RadioisotopesMaleMiceMiddle AgedPositron-Emission TomographyRadiopharmaceuticalsAntineoplastic Agents, ImmunologicalERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFluorodeoxyglucose F18Iodine-124Iodine RadioisotopesRadiopharmaceuticalsTrastuzumab124I-trastuzumabGastric cancerHER2PET/CT

Identifiers

PMID31919745
OpenAlexW3000178100

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.